EVLO Evelo Biosciences Inc.

7.67
-0.77  -9%
Previous Close 8.44
Open 8.34
Price To Book 2.07
Market Cap 245774236
Shares 32,043,577
Volume 52,478
Short Ratio
Av. Daily Volume 29,353

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b initial data due 3Q 2019.
EDP1066
Psoriasis or atopic dermatitis
Phase 2a initial data due 2H 2020.
EDP1503 and KEYTRUDA (pembrolizumab)
Melanoma
Phase 1b initial data due early 2020.
EDP1815
Psoriasis and Atopic Dermatitis
Phase 1/2 initial data due 1H 2020.
EDP1503 and KEYTRUDA (pembrolizumab)
Colorectal cancer; Triple-negative breast cancer

Latest News

  1. Evelo Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference
  2. In slow year for life science IPOs, this venture firm is making big money
  3. Evelo Biosciences, Inc. (EVLO) Q1 2019 Earnings Call Transcript
  4. Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights
  5. Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Thursday, May 2, 2019
  6. Evelo Biosciences to Present at 18th Annual Needham Healthcare Conference
  7. Evelo Biosciences to Present at 39th Annual Cowen & Co. Health Care Conference
  8. Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
  9. Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019
  10. Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA® in Patients with Metastatic Melanoma
  11. Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications
  12. Evelo Biosciences to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
  13. Evelo Enters into Clinical Trial Collaboration Agreement with Merck
  14. Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis
  15. Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections Moving into 2018
  16. Evelo Biosciences to Present at Upcoming Investor Conferences in November
  17. Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights